Bio
Kavita Iyer graduated with a Bachelor of Pharmacy from the University of Mumbai. Subsequently she earned her PhD in Medicinal Chemistry from Virginia Commonwealth University, VCU. She further pursued a post-doctoral fellowship in the Department of Physiology and Biophysics at VCU where she was trained as a structural biologist and subsequently worked as a Research Scientist. While at CAS, Kavita has worked on a wide range of topics including immuno-oncology, CRISPR therapeutics, rare diseases, and nano biosensors in Life Sciences as well as covalent inhibitors and PROTACs in Medicinal Chemistry.
バイオテクノロジー
Could xenotransplantation solve organ transplant shortages?
With the advent of genetic editing technology, researchers are increasingly able to address immuno-compatibility issues, getting closer to making organs and tissues available for transplant from animal donors to human recipients.
創薬
PPI inhibitors show promise in cancer trials
Small molecule PPI inhibitors are on the brink of improving cancer treatments
エマージング・サイエンス
共起する概念が免疫腫瘍学における新たな研究の方向性を明らかにする
概念の共起解析は、科学的発見における最新のアイデアを示し、免疫腫瘍学におけるイノベーションを推進します。
創薬
PROTACs revolutionize small molecule drugs
PROTACs are driving small molecule drug development to treat cancer, neurodegenerative diseases and more
バイオテクノロジー
Webinar: Big data insights in the quest to cure cancer
Experts discuss emerging trends in immuno-oncology, data challenges, and opportunities ahead for cancer researchers.
創薬
Emerging trends in immunotherapy and cancer
Immuno-oncology has the potential to treat cancer without sacrificing the patient's wellbeing.